Chen, Jun
Zhong, Ming-Chao
Guo, Huaijian
Davidson, Dominique
Mishel, Sabrin
Lu, Yan
Rhee, Inmoo
Pérez-Quintero, Luis-Alberto
Zhang, Shaohua
Cruz-Munoz, Mario-Ernesto
Wu, Ning
Vinh, Donald C.
Sinha, Meenal
Calderon, Virginie
Lowell, Clifford A.
Danska, Jayne S.
Veillette, André
Article History
Received: 11 May 2016
Accepted: 15 March 2017
First Online: 19 April 2017
Competing interests
: Part of A.V.’s work (distinct from the work reported herein) is supported by a grant from Bristol-Myers Squibb to study the mechanism of action of elotuzumab, which targets SLAMF7, in multiple myeloma. A.V. and J.C. have filed a patent on SLAMF7 in SIRPα–CD47 checkpoint blockade therapy. J.S.D. is an inventor on filed and awarded patents using SIRPα-protein therapeutics for treatment of haematological malignancy.